Physician profile
John A Porter
NPI 1518980747
$5,062.65
in general payments reported to CMS, 2019-2025
19 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $164 · 2021: $145 · 2022: $102 · 2023: $111 · 2024: $3,938 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $4,135 · Food and Beverage: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $4,135.40 |
| Food and Beverage | $404.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $4,135.40 | 2024-2025 | |
| Amgen INC. | $227.09 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $214.17 | 2022-2025 | |
| Abbvie INC. | $115.22 | 2020-2023 | |
| Novo Nordisk INC | $72.36 | 2021-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $55.24 | 2019-2020 | |
| Ardelyx, INC. | $51.05 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $30.81 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.32 | 2023 | Ofev |
| Abbott Laboratories | $19.82 | 2021 | |
| Sumitomo Pharma America, INC. | $17.54 | 2024 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $16.24 | 2020 | |
| Depuy Synthes Sales INC. | $15.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.26 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.39 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13.68 | 2021 | |
| Glaxosmithkline, LLC. | $13.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.96 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.